A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab

Clinical trial NCT00001805 · COMPLETED

Trial details

NCT number: NCT00001805
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Neoplasms Colonic Neoplasms Lung Neoplasms Pancreatic Neoplasms Stomach Neoplasms

Start date: 1999-03-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.